Candel Therapeutics Inc (NASDAQ:CADL) announced that its Phase 3 clinical trial results of CAN-2409 in intermediate-to-high-risk localized prostate cancer will be presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting.
The oral presentation by Dr. Glen Gejerman of Hackensack University Medical Center is scheduled for September 28 at the Moscone Center in San Francisco.